AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31718828 — intervention group
Group type: COMPARATOR
Intervention: Control (no specific control group mentioned)
Number of subjects: 204
Study 29883988 — intervention group
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (rIPC), 200 mmHg cuff pressure, 4 cycles of occlusion/reperfusion for 5 min each
Number of subjects: 10
Study 29883988 — intervention group
Group type: EXPERIMENTAL
Intervention: placebo, 120 mmHg cuff pressure, 4 cycles of occlusion/reperfusion for 5 min each
Number of subjects: 10
Study 29883988 — intervention group
Group type: COMPARATOR
Intervention: sham control, 10 mmHg pressure, 4 cycles of occlusion/reperfusion for 5 min each
Number of subjects: 10
Study 28611092 — intervention group
Group type: EXPERIMENTAL
Intervention: CTP‐656 (d9‐ivacaftor)
Number of subjects: 6
Study 28611092 — intervention group
Group type: EXPERIMENTAL
Intervention: d18‐ivacaftor
Number of subjects: 6
Study 28611092 — intervention group
Group type: COMPARATOR
Intervention: ivacaftor
Number of subjects: 6
Study 26282605 — intervention group
Group type: EXPERIMENTAL
Intervention: No-touch (NT) vein graft
Number of subjects: 54
Study 26282605 — intervention group
Group type: COMPARATOR
Intervention: Conventional (C) vein graft
Number of subjects: 54
Study 26282605 — intervention group
Group type: COMPARATOR
Intervention: Left internal thoracic artery (LITA)
Number of subjects: 54
Study 23420231 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture plus rescue medication (cetirizine)
Number of subjects: 422
Study 23420231 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture plus rescue medication (RM)
Number of subjects: 422
Study 23420231 — intervention group
Group type: COMPARATOR
Intervention: Rescue medication (RM) alone
Number of subjects: 422
Study 20144926 — intervention group
Group type: EXPERIMENTAL
Intervention: Tendon friction rubs (TFR) present at baseline
Number of subjects: 134
Study 20144926 — intervention group
Group type: EXPERIMENTAL
Intervention: Change in TFR at 6 months
Number of subjects: 134
Study 20144926 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline modified Rodnan skin score (MRSS)
Number of subjects: 134
Study 20144926 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline swollen joint count (SJC)
Number of subjects: 134
Study 17988917 — intervention group
Group type: EXPERIMENTAL
Intervention: Avaxim 80U‐Pediatric
Number of subjects: 332
Study 17988917 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix 720
Number of subjects: 332
Study 17988917 — intervention group
Group type: EXPERIMENTAL
Intervention: Havrix followed by Avaxim
Number of subjects: 332
Study 15557392 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute and large reduction in salt intake from 350 mmol/d to 10 to 20 mmol/d for 5 days
Number of subjects: 0
Study 15557392 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive increases in salt intake from 10 to 250 mmol/d by a daily amount of 50 mmol
Number of subjects: 0
Study 15557392 — intervention group
Group type: COMPARATOR
Intervention: Reduced salt intake (approximately 100 mmol/d) compared with usual salt intake (approximately 170 mmol/d)
Number of subjects: 0
Study 12545274 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean west African admixture (M) of 0.81 in cases
Number of subjects: 343
Study 12545274 — intervention group
Group type: COMPARATOR
Intervention: Mean west African admixture (M) of 0.74 in controls
Number of subjects: 343
Study 12545274 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk ratio for SLE associated with unit change in M
Number of subjects: 343
Study 12545274 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjusted risk ratio for SLE associated with unit change in M after socioeconomic status adjustment
Number of subjects: 343
Study 10372794 — intervention group
Group type: EXPERIMENTAL
Intervention: High intensity cognitive‐behavioral therapy
Number of subjects: 0
Study 10372794 — intervention group
Group type: COMPARATOR
Intervention: Low intensity therapy
Number of subjects: 0
Study 9345439 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrobulbar neuritis
Number of subjects: 223
Study 9345439 — intervention group
Group type: COMPARATOR
Intervention: Papillitis
Number of subjects: 223
Study 1816196 — intervention group
Group type: EXPERIMENTAL
Intervention: norfloxacin 400 mg bid for 10 days
Number of subjects: 60
Study 1816196 — intervention group
Group type: EXPERIMENTAL
Intervention: amoxycillin 500 mg bid plus tinidazole 500 mg bid for 15 days
Number of subjects: 60
Study 1816196 — intervention group
Group type: EXPERIMENTAL
Intervention: colloidal bismuth subcitrate (CBS) 240 mg bid for 4 weeks
Number of subjects: 60
Study 1816196 — intervention group
Group type: COMPARATOR
Intervention: amoxycillin and tinidazole (Group II)
Number of subjects: 60
Study 1816196 — intervention group
Group type: COMPARATOR
Intervention: colloidal bismuth subcitrate (Group III)
Number of subjects: 60
Study 444355 — intervention group
Group type: EXPERIMENTAL
Intervention: TFX‐SR
Number of subjects: 6
Study 444355 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 30901046 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant gut microbiome (coabundance scores dominated by Clostridiales)
Number of subjects: 715
Study 30901046 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant gut microbiome (Bacteroides‐dominated coabundance grouping)
Number of subjects: 715
Study 27988427 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-SAD (social anxiety specific cognitive behavioral therapy)
Number of subjects: 125
Study 27988427 — intervention group
Group type: EXPERIMENTAL
Intervention: CBT-GEN (generic cognitive behavioral therapy)
Number of subjects: 125
Study 27988427 — intervention group
Group type: COMPARATOR
Intervention: WLC (wait list control)
Number of subjects: 125
Study 25532493 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS-guided anesthesia
Number of subjects: 130
Study 25532493 — intervention group
Group type: COMPARATOR
Intervention: HP-guided anesthesia
Number of subjects: 130
Study 23620930 — intervention group
Group type: EXPERIMENTAL
Intervention: Flying needling therapy
Number of subjects: 315
Study 23620930 — intervention group
Group type: COMPARATOR
Intervention: Estazolam
Number of subjects: 315
Study 23620930 — intervention group
Group type: COMPARATOR
Intervention: Non-acupoint acupuncture
Number of subjects: 315
Study 21073330 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-surgical periodontal therapy
Number of subjects: 52
Study 19125236 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC 0.02%
Number of subjects: 32
Study 19125236 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC 0.05%
Number of subjects: 32
Study 19125236 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC 0.08%
Number of subjects: 32
Study 19125236 — intervention group
Group type: EXPERIMENTAL
Intervention: BAC 0.10%
Number of subjects: 32
Study 19125236 — intervention group
Group type: COMPARATOR
Intervention: Alcohol-placebo
Number of subjects: 32
Study 16953374 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital X-ray radiogrammetry (DXR)
Number of subjects: 161
Study 16953374 — intervention group
Group type: COMPARATOR
Intervention: Quantitative ultrasound (QUS)
Number of subjects: 161
Study 15073402 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose 100 mg 3 times daily
Number of subjects: 132
Study 15073402 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132
Study 15073402 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 132
Study 11458482 — intervention group
Group type: EXPERIMENTAL
Intervention: Active multiprofessional risk factor intervention
Number of subjects: 150
Study 11458482 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 150
Study 10234673 — intervention group
Group type: EXPERIMENTAL
Intervention: Rest + GTN tetrofosmin imaging
Number of subjects: 30
Study 8790654 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief advice during one consultation supplemented by a self-help booklet
Number of subjects: 105
Study 8790654 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 105
Study 2568247 — intervention group
Group type: EXPERIMENTAL
Intervention: Famotidine 40 mg at bedtime
Number of subjects: 195
Study 2568247 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg twice a day
Number of subjects: 195
Study 1242823 — intervention group
Group type: EXPERIMENTAL
Intervention: Masteril (drostanolone propionate)
Number of subjects: 0
Study 1242823 — intervention group
Group type: COMPARATOR
Intervention: Oophorectomy
Number of subjects: 0
Study 1242823 — intervention group
Group type: COMPARATOR
Intervention: Durabolin (nandrolone phenylpropionate)
Number of subjects: 0
Study 1242823 — intervention group
Group type: EXPERIMENTAL
Intervention: Oestrogens (ethinyl oestradiol)
Number of subjects: 0
Study 31914075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mosapride citrate with a split-dose of PEG plus ascorbic acid
Number of subjects: 257
Study 31037359 — intervention group
Group type: EXPERIMENTAL
Intervention: Parity
Number of subjects: 6500
Study 31037359 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactation
Number of subjects: 6500
Study 31037359 — intervention group
Group type: COMPARATOR
Intervention: Control (no parity or lactation)
Number of subjects: 6500
Study 28573932 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity warfarin (INR maintained at 1.5 to 2.0) in group A
Number of subjects: 101
Study 28573932 — intervention group
Group type: COMPARATOR
Intervention: Standard-intensity warfarin (INR maintained at 2.0 to 2.5) in group B
Number of subjects: 101
Study 24722790 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation
Number of subjects: 10
Study 24722790 — intervention group
Group type: COMPARATOR
Intervention: Intermittent pneumatic compression
Number of subjects: 10
Study 23008110 — intervention group
Group type: EXPERIMENTAL
Intervention: letrozole + tamoxifen and human menopausal gonadotropin (HMG)
Number of subjects: 130
Study 23008110 — intervention group
Group type: COMPARATOR
Intervention: placebo instead of tamoxifen
Number of subjects: 130
Study 21992565 — intervention group
Group type: COMPARATOR
Intervention: Pulmonary autograft (PA) in group 1 (n = 20)
Number of subjects: 120
Study 21992565 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical prosthesis (MP) in group 1 (n = 20)
Number of subjects: 120
Study 21992565 — intervention group
Group type: COMPARATOR
Intervention: Stentless bioprosthesis (CE Prima Plus) in group 2 (n = 20)
Number of subjects: 120
Study 21992565 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical prosthesis (MP) in group 2 (n = 20)
Number of subjects: 120
Study 21992565 — intervention group
Group type: COMPARATOR
Intervention: Stentless bioprosthesis (CE Prima Plus) in group 3 (n = 20)
Number of subjects: 120
Study 21992565 — intervention group
Group type: EXPERIMENTAL
Intervention: Stented bioprosthesis (CE Perimount) in group 3 (n = 20)
Number of subjects: 120
Study 18608419 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy interventions
Number of subjects: 47
Study 18608419 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 47
Study 17598506 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic vaccines for primary prevention
Number of subjects: 0
Study 17598506 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV DNA tests for secondary prevention
Number of subjects: 0
Study 15076015 — intervention group
Group type: EXPERIMENTAL
Intervention: Temazepam 20 mg for 2 weeks
Number of subjects: 38
Study 15076015 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 15076015 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated telephoned questionnaires
Number of subjects: 38
Study 15076015 — intervention group
Group type: EXPERIMENTAL
Intervention: Pencil-and-paper questionnaires
Number of subjects: 38
Study 11696073 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg slow-release caffeine
Number of subjects: 12
Study 11696073 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 9566820 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon treatment
Number of subjects: 103
Study 9566820 — intervention group
Group type: EXPERIMENTAL
Intervention: NS5 reactivity
Number of subjects: 103
Study 7930153 — intervention group
Group type: EXPERIMENTAL
Intervention: District co-ordinating service for terminal care
Number of subjects: 0
Study 3276409 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous streptokinase (IVSK)
Number of subjects: 368
Study 3276409 — intervention group
Group type: COMPARATOR
Intervention: Standard therapy (Control)
Number of subjects: 368
Study 30599145 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted Auditory Training (TAT)
Number of subjects: 49
Study 30599145 — intervention group
Group type: COMPARATOR
Intervention: Computer Games (CG)
Number of subjects: 49
Study 30265194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision rule based on major and minor criteria for predicting intracranial hypertension (ICP).
Number of subjects: 281
Study 30265194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision rule with higher ICP cutoffs.
Number of subjects: 281
Study 30265194 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision rule validated in North American cohort.
Number of subjects: 281
Study 26320523 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg intravenously + Metoclopramide 10 mg intravenously
Number of subjects: 208
Study 26320523 — intervention group
Group type: COMPARATOR
Intervention: Placebo + Metoclopramide 10 mg intravenously
Number of subjects: 208
Study 24119192 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Restrictive Pressure (IRP) of 40-45 mmHg
Number of subjects: 0
Study 24119192 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Restrictive Pressure (IRP) of 60-65 mmHg
Number of subjects: 0
Study 24119192 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 22665541 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab added to gemcitabine/cisplatin
Number of subjects: 115
Study 22665541 — intervention group
Group type: COMPARATOR
Intervention: Placebo with gemcitabine/cisplatin
Number of subjects: 115
Study 22665541 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pretreatment plasma VEGF concentration
Number of subjects: 115
Study 18951860 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine patch (LP) applied on the anterior abdominal wall
Number of subjects: 30
Study 18951860 — intervention group
Group type: COMPARATOR
Intervention: No lidocaine patch applied
Number of subjects: 30
Study 17574644 — intervention group
Group type: EXPERIMENTAL
Intervention: Flickering dots presented at 4 degrees eccentricity
Number of subjects: 0
Study 17574644 — intervention group
Group type: EXPERIMENTAL
Intervention: Flickering dots presented at 14 degrees eccentricity
Number of subjects: 0
Study 17574644 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper visual field presentation
Number of subjects: 0
Study 17574644 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower visual field presentation
Number of subjects: 0
Study 16128595 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg/mL oral suspension
Number of subjects: 18
Study 16128595 — intervention group
Group type: EXPERIMENTAL
Intervention: 200mg tablets
Number of subjects: 18
Study 16128595 — intervention group
Group type: COMPARATOR
Intervention: 800mg tablets (reference)
Number of subjects: 18
Study 12081991 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting plus abciximab
Number of subjects: 48
Study 12081991 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting alone
Number of subjects: 48
Study 12081991 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-PCI vessel)
Number of subjects: 48
Study 9620330 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial embolization (TAE)
Number of subjects: 80
Study 9620330 — intervention group
Group type: COMPARATOR
Intervention: Symptomatic treatment
Number of subjects: 80
Study 7666704 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving counseling
Number of subjects: 293
Study 7666704 — intervention group
Group type: EXPERIMENTAL
Intervention: Phone call support
Number of subjects: 293
Study 7666704 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 293
Study 2571114 — intervention group
Group type: EXPERIMENTAL
Intervention: Dipivefrin hydrochloride 0.1% twice daily
Number of subjects: 32
Study 2571114 — intervention group
Group type: COMPARATOR
Intervention: Fellow eyes (control group)
Number of subjects: 32
Study 15848620 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-J stent (DJS) placed during Lich-Gregoir ureterocystotomy
Number of subjects: 42
Study 15848620 — intervention group
Group type: COMPARATOR
Intervention: No DJS insertion during Lich-Gregoir ureterostomy
Number of subjects: 42
Study 31654580 — intervention group
Group type: EXPERIMENTAL
Intervention: Bar implant overdentures (BOD)
Number of subjects: 24
Study 31654580 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilient telescopic implant overdentures (TOD)
Number of subjects: 24
Study 31654580 — intervention group
Group type: EXPERIMENTAL
Intervention: Stud implant overdentures (SOD)
Number of subjects: 24
Study 31654580 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenching hard food
Number of subjects: 24
Study 31654580 — intervention group
Group type: EXPERIMENTAL
Intervention: Clenching side (ch2)
Number of subjects: 24
Study 31586772 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg administered 1 hour before bedtime for 12 weeks
Number of subjects: 252
Study 31586772 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered 1 hour before bedtime for 12 weeks
Number of subjects: 252
Study 31586772 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 25 mg
Number of subjects: 252
Study 31586772 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 28342282 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate-release tacrolimus (IR-TAC)
Number of subjects: 23
Study 28342282 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release tacrolimus (ER-TAC)
Number of subjects: 23
Study 28342282 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolic acid (MPA)
Number of subjects: 23
Study 25778997 — intervention group
Group type: EXPERIMENTAL
Intervention: Removal of the tensor tympani muscle tendon (group 1)
Number of subjects: 212
Study 25778997 — intervention group
Group type: COMPARATOR
Intervention: Retention of the tensor tympani muscle tendon (group 2)
Number of subjects: 212
Study 23242431 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (fracture clinic initiated assessment)
Number of subjects: 66
Study 23242431 — intervention group
Group type: COMPARATOR
Intervention: Control group (GP initiated assessment)
Number of subjects: 66
Study 21777634 — intervention group
Group type: EXPERIMENTAL
Intervention: Low viscous alginate fibre‐based preloads of 3% concentration (500 ml volume) three times a day
Number of subjects: 24
Study 21777634 — intervention group
Group type: COMPARATOR
Intervention: Control group (calorie-restricted diet without alginate preloads)
Number of subjects: 24
Study 17980952 — intervention group
Group type: EXPERIMENTAL
Intervention: Isosorbide mononitrate (ISMN) vaginal gel 80 mg
Number of subjects: 65
Study 17980952 — intervention group
Group type: EXPERIMENTAL
Intervention: Misoprostol vaginal gel 200 microg
Number of subjects: 65
Study 17980952 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-S (hygroscopical cervical dilator)
Number of subjects: 65
Study 17980952 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilapan-S
Number of subjects: 65
Study 17980952 — intervention group
Group type: EXPERIMENTAL
Intervention: ISMN
Number of subjects: 65
Study 16894289 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 0
Study 16894289 — intervention group
Group type: COMPARATOR
Intervention: Combined-modality therapy (chemotherapy + radiotherapy)
Number of subjects: 0
Study 16894289 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination chemotherapy including gemcitabine
Number of subjects: 0
Study 16894289 — intervention group
Group type: EXPERIMENTAL
Intervention: Positron emission tomography after one or two cycles of chemotherapy
Number of subjects: 0
Study 12660125 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-based product (0.3% concentration); rinsed three times a day for 30s from the beginning of chemotherapy until the end of leukopenia
Number of subjects: 47
Study 12660125 — intervention group
Group type: COMPARATOR
Intervention: Control group (amine-stannous fluoride combination); rinsed three times a day for 30s from the beginning of chemotherapy until the end of leukopenia
Number of subjects: 47
Study 12660125 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorhexidine-based product (0.3% concentration); separate analysis for patients with <1000 leucocytes/microL for a minimum of three days
Number of subjects: 47
Study 12660125 — intervention group
Group type: COMPARATOR
Intervention: Control group (amine-stannous fluoride combination); separate analysis for patients with <1000 leucocytes/microL for a minimum of three days
Number of subjects: 47
Study 10773060 — intervention group
Group type: EXPERIMENTAL
Intervention: Uninfected exposed hemophiliacs
Number of subjects: 7
Study 10773060 — intervention group
Group type: COMPARATOR
Intervention: Infected hemophiliacs
Number of subjects: 7
Study 10773060 — intervention group
Group type: COMPARATOR
Intervention: Healthy donors (controls)
Number of subjects: 7
Study 9361936 — intervention group
Group type: EXPERIMENTAL
Intervention: CMVIG prophylaxis
Number of subjects: 162
Study 9361936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 162
Study 1469516 — intervention group
Group type: EXPERIMENTAL
Intervention: Powdered fortifier (PF)
Number of subjects: 35
Study 1469516 — intervention group
Group type: COMPARATOR
Intervention: Liquid supplement (LS)
Number of subjects: 35
Study 3847401 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogen peroxide (H2O2) instillation in drainage bags
Number of subjects: 0
Study 3847401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no H2O2 instillation)
Number of subjects: 0
Study 31978580 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (LFX) resistant isolates from 2005 and 2015
Number of subjects: 542
Study 31978580 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin (LFX) resistance in 2015
Number of subjects: 542